282 related articles for article (PubMed ID: 11721759)
21. The economic impact of GERD and PUD: examination of direct and indirect costs using a large integrated employer claims database.
Joish VN; Donaldson G; Stockdale W; Oderda GM; Crawley J; Sasane R; Joshua-Gotlib S; Brixner DI
Curr Med Res Opin; 2005 Apr; 21(4):535-44. PubMed ID: 15899102
[TBL] [Abstract][Full Text] [Related]
22. Budget impact of tegaserod on a managed care organization formulary.
Bloom MA; Barghout V; Kahler KH; Bentkover J; Kurth H; Gralnek IM; Spiegel BM
Am J Manag Care; 2005 Apr; 11(1 Suppl):S27-34. PubMed ID: 15926761
[TBL] [Abstract][Full Text] [Related]
23. Increased urine catecholamines and cortisol in women with irritable bowel syndrome.
Heitkemper M; Jarrett M; Cain K; Shaver J; Bond E; Woods NF; Walker E
Am J Gastroenterol; 1996 May; 91(5):906-13. PubMed ID: 8633579
[TBL] [Abstract][Full Text] [Related]
24. How does comorbidity affect cost of health care in patients with irritable bowel syndrome? A cohort study in general practice.
Johansson PA; Farup PG; Bracco A; Vandvik PO
BMC Gastroenterol; 2010 Mar; 10():31. PubMed ID: 20233451
[TBL] [Abstract][Full Text] [Related]
25. Healthcare use and costs of primary and secondary care patients with prostatitis.
Turner JA; Ciol MA; Von Korff M; Rothman I; Berger RE
Urology; 2004 Jun; 63(6):1031-5. PubMed ID: 15183941
[TBL] [Abstract][Full Text] [Related]
26. Coping strategies and interpersonal support in patients with irritable bowel syndrome and inflammatory bowel disease.
Jones MP; Wessinger S; Crowell MD
Clin Gastroenterol Hepatol; 2006 Apr; 4(4):474-81. PubMed ID: 16616353
[TBL] [Abstract][Full Text] [Related]
27. Health care costs associated with posttraumatic stress disorder symptoms in women.
Walker EA; Katon W; Russo J; Ciechanowski P; Newman E; Wagner AW
Arch Gen Psychiatry; 2003 Apr; 60(4):369-74. PubMed ID: 12695314
[TBL] [Abstract][Full Text] [Related]
28. Increased medical costs of a population-based sample of depressed elderly patients.
Katon WJ; Lin E; Russo J; Unutzer J
Arch Gen Psychiatry; 2003 Sep; 60(9):897-903. PubMed ID: 12963671
[TBL] [Abstract][Full Text] [Related]
29. A population-based case-control study of work and psychosocial problems in patients with irritable bowel syndrome--women are more seriously affected than men.
Faresjö A; Grodzinsky E; Johansson S; Wallander MA; Timpka T; Akerlind I
Am J Gastroenterol; 2007 Feb; 102(2):371-9. PubMed ID: 17156145
[TBL] [Abstract][Full Text] [Related]
30. The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome.
Creed F; Fernandes L; Guthrie E; Palmer S; Ratcliffe J; Read N; Rigby C; Thompson D; Tomenson B;
Gastroenterology; 2003 Feb; 124(2):303-17. PubMed ID: 12557136
[TBL] [Abstract][Full Text] [Related]
31. Work loss costs due to peptic ulcer disease and gastroesophageal reflux disease in a health maintenance organization.
Henke CJ; Levin TR; Henning JM; Potter LP
Am J Gastroenterol; 2000 Mar; 95(3):788-92. PubMed ID: 10710076
[TBL] [Abstract][Full Text] [Related]
32. Is irritable bowel syndrome more common in patients presenting with bacterial gastroenteritis? A community-based, case-control study.
Parry SD; Stansfield R; Jelley D; Gregory W; Phillips E; Barton JR; Welfare MR
Am J Gastroenterol; 2003 Feb; 98(2):327-31. PubMed ID: 12591050
[TBL] [Abstract][Full Text] [Related]
33. Prevalence and risk factors for overlaps between gastroesophageal reflux disease, dyspepsia, and irritable bowel syndrome: a population-based study.
Lee SY; Lee KJ; Kim SJ; Cho SW
Digestion; 2009; 79(3):196-201. PubMed ID: 19342860
[TBL] [Abstract][Full Text] [Related]
34. Healthcare utilization and costs of patients with rosacea in an insured population.
Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
[TBL] [Abstract][Full Text] [Related]
35. Fibromyalgia in the irritable bowel syndrome: studies of prevalence and clinical implications.
Sperber AD; Atzmon Y; Neumann L; Weisberg I; Shalit Y; Abu-Shakrah M; Fich A; Buskila D
Am J Gastroenterol; 1999 Dec; 94(12):3541-6. PubMed ID: 10606316
[TBL] [Abstract][Full Text] [Related]
36. Effectiveness of tegaserod therapy on GI-related resource utilization in a managed care population.
Stephenson JJ; Barghout V; Kahler KH; Fernandes J; Beaulieu JF; Joo S; Boccuzzi SJ
Am J Manag Care; 2005 Apr; 11(1 Suppl):S35-42. PubMed ID: 15926762
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of trimebutine therapy in patients with gastroesophageal reflux disease and irritable bowel syndrome.
Kountouras J; Chatzopoulos D; Zavos C; Boura P; Venizelos J; Kalis A
Hepatogastroenterology; 2002; 49(43):193-7. PubMed ID: 11941952
[TBL] [Abstract][Full Text] [Related]
38. Psychological factors in irritable bowel syndrome: a population-based study of patients, non-patients and controls.
Weinryb RM; Osterberg E; Blomquist L; Hultcrantz R; Krakau I; Asberg M
Scand J Gastroenterol; 2003 May; 38(5):503-10. PubMed ID: 12795460
[TBL] [Abstract][Full Text] [Related]
39. Health care utilization and costs of Alzheimer's disease: the role of co-morbid conditions, disease stage, and pharmacotherapy.
Fillit H; Hill JW; Futterman R
Fam Med; 2002; 34(7):528-35. PubMed ID: 12144008
[TBL] [Abstract][Full Text] [Related]
40. Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors.
Simrén M; Axelsson J; Gillberg R; Abrahamsson H; Svedlund J; Björnsson ES
Am J Gastroenterol; 2002 Feb; 97(2):389-96. PubMed ID: 11866278
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
